Article
FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor.
Oncotarget - 15 Aug 2014
Azuma Koichi, Kawahara Akihiko, Sonoda Kahori, Nakashima Kazutaka, Tashiro Kousuke, Watari Kosuke, Izumi Hiroto, Kage Masayoshi, Kuwano Michihiko, Ono Mayumi, Hoshino Tomoaki
Abstract excerpt
Most NSCLC patients with EGFR mutations benefit from treatment with EGFR-TKIs, but the clinical efficacy of EGFR-TKIs is limited by the appearance of drug resistance. Multiple kinase inhibitors of EGFR family proteins such as afatinib have been newly developed to overcome such drug resistance. We established afatinib-resistant cell lines after chronic exposure of activating EGFR mutation-positive PC9 cells to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.